Global Remicade (Infliximab) and Biosimilar Market Growth 2023-2029

Global Remicade (Infliximab) and Biosimilar Market Growth 2023-2029

The global Remicade (Infliximab) and Biosimilar market size is projected to grow from US$ 2494.5 million in 2022 to US$ 3703.9 million in 2029; it is expected to grow at a CAGR of 5.8% from 2023 to 2029.

United States market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Remicade (Infliximab) and Biosimilar players cover J & J, Pfizer, Organon and Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

LPI (LP Information)' newest research report, the “Remicade (Infliximab) and Biosimilar Industry Forecast” looks at past sales and reviews total world Remicade (Infliximab) and Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Remicade (Infliximab) and Biosimilar sales for 2023 through 2029. With Remicade (Infliximab) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Remicade (Infliximab) and Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Remicade (Infliximab) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Remicade (Infliximab) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Remicade (Infliximab) and Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Remicade (Infliximab) and Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Remicade (Infliximab) and Biosimilar.

This report presents a comprehensive overview, market shares, and growth opportunities of Remicade (Infliximab) and Biosimilar market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Brand
Biosimilar

Segmentation by application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
J & J
Pfizer
Organon
Amgen

Key Questions Addressed in this Report

What is the 10-year outlook for the global Remicade (Infliximab) and Biosimilar market?

What factors are driving Remicade (Infliximab) and Biosimilar market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Remicade (Infliximab) and Biosimilar market opportunities vary by end market size?

How does Remicade (Infliximab) and Biosimilar break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.